HDL and Triglycerides in the Year 2011: What Might the NCEP ATP IV Guidelines Look Like?

Dr. Nanette K. Wenger from the Emory University School of Medicine moderated the topic "HDL and Triglycerides in the Year 2011," with Drs. Christie Ballantyne from the Baylor College of Medicine and Michael Davidson from the University of Chicago School of Medicine participating. The discussion focused primarily on: (1) speculation as to the recommendations that might be made in the NCEP ATP IV Guidelines, particularly about non-HDL cholesterol (2) gender specific recommendations with emphasis on the AHA guidelines, (3) diabetic versus non-diabetic patients with high riglycerides and low HDL levels, (4) clarifying often misquoted clinical trial data, including ACCORD and VA-HIT, (5) potential for drugs to raise HDL holesterol by CETP inhibition, (6) current trials underway evaluating the use of niacin and statin therapy, (7) Framingham risk evaluation using total holesterol to HDL ratio, (8) trial data providing insights to metabolic syndrome therapy, (9) lifestyle modifications for raising HDL, (10) treatment for women with very high HDL levels, and (11) whether reducing LDL beyond a floor level provides significant benefits. (Med Roundtable Cardiovasc Ed. 2011;2(2):72-80) ©2011 FoxP2 Media, LLC